about
Global regulation of alternative splicing during myogenic differentiationModeling ALS and FTD with iPSC-derived neuronsThe role of tau in neurodegenerative diseases and its potential as a therapeutic targetPrion-like properties of Tau protein: the importance of extracellular Tau as a therapeutic targetEarly etiology of Alzheimer's disease: tipping the balance toward autophagy or endosomal dysfunction?Tau and tauopathiesTargeting mRNA for Alzheimer's and related dementias.Genetic variants associated with neurodegenerative Alzheimer disease in natural modelsThe homologous carboxyl-terminal domains of microtubule-associated protein 2 and TAU induce neuronal dysfunction and have differential fates in the evolution of neurofibrillary tanglesAmetantrone-based compounds as potential regulators of Tau pre-mRNA alternative splicing.Differential effect of three-repeat and four-repeat tau on mitochondrial axonal transport.Template-directed synthesis of a small molecule-antisense conjugate targeting an mRNA structure.Hsc70 rapidly engages tau after microtubule destabilizationTau potentiates nerve growth factor-induced mitogen-activated protein kinase signaling and neurite initiation without a requirement for microtubule binding.Molecular insights into the pathogenesis of Alzheimer's disease and its relationship to normal agingTau binds to lipid membrane surfaces via short amphipathic helices located in its microtubule-binding repeatsInteractions between amyloid-β and Tau fragments promote aberrant aggregates: implications for amyloid toxicityProtein tau: prime cause of synaptic and neuronal degeneration in Alzheimer's disease.Regulation of alternative splicing of tau exon 10 by 9G8 and Dyrk1AA novel MAPT mutation, G55R, in a frontotemporal dementia patient leads to altered Tau function.The cellular distribution and Ser262 phosphorylation of tau protein are regulated by BDNF in vitro.Tau splicing and the intricacies of dementia.Advances in tau-based drug discovery.Structure-Based Small Molecule Modulation of a Pre-Amyloid State: Pharmacological Enhancement of IAPP Membrane-Binding and Toxicity.The Maze of APP Processing in Alzheimer's Disease: Where Did We Go Wrong in Reasoning?Transgenic mouse and cell culture models demonstrate a lack of mechanistic connection between endoplasmic reticulum stress and tau dysfunction.Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases.Assessment of Olfactory Function in MAPT-Associated Neurodegenerative Disease Reveals Odor-Identification Irreproducibility as a Non-Disease-Specific, General Characteristic of Olfactory DysfunctionTargeting protein aggregation for the treatment of degenerative diseasesNatural products as a source of Alzheimer's drug leads.Common variants at 12q15 and 12q24 are associated with infant head circumference.FTD and ALS: a tale of two diseasesSelective vulnerability to neurodegenerative disease: the curious case of Prion Protein.PSF suppresses tau exon 10 inclusion by interacting with a stem-loop structure downstream of exon 10.Mediators of tau phosphorylation in the pathogenesis of Alzheimer's disease.Biochemistry and cell biology of tau protein in neurofibrillary degenerationBehind the curtain of tauopathy: a show of multiple players orchestrating tau toxicity.C-terminal truncation of GSK-3β enhances its dephosphorylation by PP2A.Unlocking truths of γ-secretase in Alzheimer's disease: what is the translational potential?Targeting a pre-mRNA structure with bipartite antisense molecules modulates tau alternative splicing.
P2860
Q24632881-9143882A-CADF-4521-9E75-316CF661FC0AQ26783672-170F4D8D-7870-4737-B7D5-F08775F7141AQ27005032-83D81B49-4F44-42B0-9590-2227FB17383BQ27021159-3B71D3C0-8609-4C64-BACF-E9E601B81513Q27026907-920B12BA-7628-4543-B945-D316F31C0589Q27027415-48FE79DD-8FBE-4C03-BC96-8378464FEF30Q27687153-B63542B7-C72A-4EE1-8552-9669535B6DDAQ28079843-7833A56B-4E2D-4C4B-9FBB-122535A0025FQ28540122-2F3A4762-7D56-4625-8D33-BEFE64FCBA39Q30867681-F75421D9-EECD-494F-8014-F7B46467FACBQ33700664-CFA154A0-2BEF-452C-8737-FCA5A3E83F92Q33835923-43229E91-A656-4780-B78D-49827A72908BQ33883285-61990339-7090-4DC8-A0F8-0609E5B0D857Q33911246-6EF5A740-85B4-41CB-B396-649A53049306Q34117787-733DE737-716B-4745-96AC-FB17A8A5B650Q34203739-26221129-2CB1-4226-BD09-1A05ABCE19EFQ34243172-05B4BD55-F7A2-4950-A18A-0BFE58D49DBFQ34283149-DA4771E7-FA22-497C-BB2B-602168B5A3AAQ34900413-7E0F46E8-FFE0-4675-9B6C-D41F4CBB262DQ35006348-E0EFEDE9-E8E5-43F4-9B95-7B924AFE782DQ35117516-9C3D7F99-ADBC-414B-B61A-F9E4413447FEQ35226142-4CA1AFE3-AD60-4A4E-873E-E4FE75B6AE34Q35321539-85633AC2-268C-4E86-A1B3-A021BC638E80Q35628125-E97105A4-A112-47C9-B260-BF57D86806B7Q35659159-123594FC-6402-4401-B8AF-729A463B0FBDQ36028813-69027E0B-C76E-4FA4-B8A1-28F95C2688CCQ36083108-6660A9C8-7774-4137-A765-204719741B31Q36195000-027CF43C-E7BA-4CC6-BC21-705A0E9233B2Q36235980-D7F5BB55-ADB9-468B-A19B-464FD65D6BFAQ37029561-612DFC5E-FB99-4462-AC27-B664970CD9BCQ37173595-D8A81E5A-0487-441A-8AB5-64D39D1C44EFQ37241079-A5E2BEA0-D37A-48E6-8926-8BF2086A06B2Q37438476-35BB6D56-9164-46E7-9E58-50724A6BBCE5Q37483533-F2F16BCD-0075-43E8-9C23-A0491A9B9390Q37630546-92A6D5F8-9FA3-4D62-803B-D46369C35EAEQ38023859-E1BD15D6-9E56-40B3-B13E-8FCBEEB703FDQ38592451-2BE3715F-BAAC-4E6B-96C0-E138127F5BDAQ38713373-5A2F77FB-940F-4C9C-BCDF-67972C9F150EQ39285976-9048B8F3-CD0F-435C-86E8-B81261510033Q39306317-D86DDC6D-4630-409D-96B0-2C63F5B40DCC
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tau mutations in neurodegenerative diseases.
@en
Tau mutations in neurodegenerative diseases.
@nl
type
label
Tau mutations in neurodegenerative diseases.
@en
Tau mutations in neurodegenerative diseases.
@nl
prefLabel
Tau mutations in neurodegenerative diseases.
@en
Tau mutations in neurodegenerative diseases.
@nl
P2860
P356
P1476
Tau mutations in neurodegenerative diseases.
@en
P2093
Michael S Wolfe
P2860
P304
P356
10.1074/JBC.R800013200
P407
P577
2008-10-22T00:00:00Z